Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

NCT06991920 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Adult ALL
MPAL

Interventions

DRUG: Blinatumomab
DRUG: Venetoclax

Sponsor

Institute of Hematology & Blood Diseases Hospital, China